Mapping of the binding sites for the OX 1 orexin receptor antagonist, SB-334867, using orexin/hypocretin receptor chimaeras

Neuroscience Letters

Volumn 506, Issue 1, 2012, Pages 111-115

  Putula, Jaana ^a   Kukkonen, Jyrki P ^a  

^a UNIVERSITY OF HELSINKI   (Finland)

Author keywords

Hypocretin; Orexin; OX 1 receptor; OX 2 receptor; SB 334867

Indexed keywords

1 (2 METHYL 6 BENZOXAZOLYL) 3 (1,5 NAPHTHYRIDIN 4 YL)UREA; INOSITOL PHOSPHATE; OREXIN 1 RECEPTOR; OREXIN 2 RECEPTOR;

AGONIST; ARTICLE; BINDING AFFINITY; BINDING SITE; DRUG DESIGN; DRUG RECEPTOR BINDING; ENZYME ACTIVITY; HUMAN; PRIORITY JOURNAL; SYNTHESIS;

BENZOXAZOLES; BINDING SITES; CHIMERA; HEK293 CELLS; HUMANS; INOSITOL PHOSPHATES; MODELS, MOLECULAR; PROTEIN BINDING; RECEPTORS, G-PROTEIN-COUPLED; RECEPTORS, NEUROPEPTIDE; TRANSFECTION; TRITIUM; UREA;

EID: 84855198879     PISSN: 03043940     EISSN: 18727972     Source Type: Journal    
DOI: 10.1016/j.neulet.2011.10.061     Document Type: Article

References (22)

1. Ammoun S., Holmqvist T., Shariatmadari R., Oonk H.B., Detheux M., Parmentier M., Åkerman K.E., Kukkonen J.P. Distinct recognition of OX1 and OX2 receptors by orexin peptides. J. Pharmacol. Exp. Ther. 2003, 305:507-514.
2. Darker J.G., Porter R.A., Eggleston D.S., Smart D., Brough S.J., Sabido-David C., Jerman J.C. Structure-activity analysis of truncated orexin-A analogues at the orexin-1 receptor. Bioorg. Med. Chem. Lett. 2001, 11:737-740.
3. Holmqvist T., Åkerman K.E.O., Kukkonen J.P. High specificity of human orexin receptors for orexins over neuropeptide Y and other neuropeptides. Neurosci. Lett. 2001, 305:177-180.
4. Holmqvist T., Åkerman K.E.O., Kukkonen J.P. Orexin signaling in recombinant neuron-like cells. FEBS Lett. 2002, 526:11-14.
5. Johansson L., Ekholm M.E., Kukkonen J.P. Regulation of OX(1) orexin/hypocretin receptor-coupling to phospholipase C by Ca(2+) influx. Br. J. Pharmacol. 2007, 150:97-104.
6. Kukkonen J.P., Holmqvist T., Ammoun S., Åkerman K.E. Functions of the orexinergic/hypocretinergic system. Am. J. Physiol. Cell Physiol. 2002, 283:C1567-C1591.
7. Kukkonen J.P., Åkerman K.E.O. Intracellular signal pathways utilized by the hypocretin/orexin receptors. Hypocretins as Integrators of Physiological Signals 2005, 221-231. Springer Science+Business Media, Berlin. L. de Lecea, J.G. Sutcliffe (Eds.).
8. Lang M., Bufe B., De Pol S., Reiser O., Meyerhof W., Beck-Sickinger A.G. Structural properties of orexins for activation of their receptors. J. Pept. Sci. 2006, 12:258-266.
9. Lang M., Soll R.M., Durrenberger F., Dautzenberg F.M., Beck-Sickinger A.G. Structure-activity studies of orexin A and orexin B at the human orexin 1 and orexin 2 receptors led to orexin 2 receptor selective and orexin 1 receptor preferring ligands. J. Med. Chem. 2004, 47:1153-1160.
10. 2+ influx pathway necessary for coupling to phospholipase C. J. Biol. Chem. 2000, 275:30806-30812.
11. Malherbe P., Roche O., Marcuz A., Kratzeisen C., Wettstein J.G., Bissantz C. Mapping the binding pocket of dual antagonist almorexant to human orexin 1 and orexin 2 receptors: comparison with the selective OX1 (SB-674042) and OX2 (EMPA) antagonists. Mol. Pharmacol. 2010, 78:81-93.
12. Okumura T., Takeuchi S., Motomura W., Yamada H., Egashira Si S., Asahi S., Kanatani A., Ihara M., Kohgo Y. Requirement of intact disulfide bonds in orexin-A-induced stimulation of gastric acid secretion that is mediated by OX1 receptor activation. Biochem. Biophys. Res. Commun. 2001, 280:976-981.
13. Porter R.A., Chan W.N., Coulton S., Johns A., Hadley M.S., Widdowson K., Jerman J.C., Brough S.J., Coldwell M., Smart D., Jewitt F., Jeffrey P., Austin N. 1,3-Biarylureas as selective non-peptide antagonists of the orexin-1 receptor. Bioorg. Med. Chem. Lett. 2001, 11:1907-1910.
14. Putula J., Turunen P.M., Jäntti M.H., Ekholm M.E., Kukkonen J.P. Agonist ligand discrimination by the two orexin receptors depends on the expression system. Neurosci. Lett. 2011, 494:57-60.
15. Putula J., Turunen P.M., Johansson L., Näsman J., Ra R., Korhonen L., Kukkonen J.P. Orexin/hypocretin receptor chimaeras reveal structural features important for orexin peptide distinction. FEBS Lett. 2011, 585:1368-1374.
16. Rasmussen S.G., Choi H.J., Fung J.J., Pardon E., Casarosa P., Chae P.S., Devree B.T., Rosenbaum D.M., Thian F.S., Kobilka T.S., Schnapp A., Konetzki I., Sunahara R.K., Gellman S.H., Pautsch A., Steyaert J., Weis W.I., Kobilka B.K. Structure of a nanobody-stabilized active state of the beta(2) adrenoceptor. Nature 2011, 469:175-180.
17. Roecker A.J., Coleman P.J. Orexin receptor antagonists: medicinal chemistry and therapeutic potential. Curr. Top. Med. Chem. 2008, 8:977-987.
18. Scammell T.E., Winrow C.J. Orexin receptors: pharmacology and therapeutic opportunities. Annu. Rev. Pharmacol. Toxicol. 2011, 51:243-266.
19. Smart D., Sabido-David C., Brough S.J., Jewitt F., Johns A., Porter R.A., Jerman J.C. SB-334867-A: the first selective orexin-1 receptor antagonist. Br. J. Pharmacol. 2001, 132:1179-1182.
20. Tran D.T., Bonaventure P., Hack M., Mirzadegan T., Dvorak C., Letavic M., Carruthers N., Lovenberg T., Sutton S.W. Chimeric, mutant orexin receptors show key interactions between orexin receptors, peptides and antagonists. Eur. J. Pharmacol. 2011, 667:120-128.
21. Wu B., Chien E.Y., Mol C.D., Fenalti G., Liu W., Katritch V., Abagyan R., Brooun A., Wells P., Bi F.C., Hamel D.J., Kuhn P., Handel T.M., Cherezov V., Stevens R.C. Structures of the CXCR4 chemokine GPCR with small-molecule and cyclic peptide antagonists. Science 2010, 330:1066-1071.
22. Xu F., Wu H., Katritch V., Han G.W., Jacobson K.A., Gao Z.G., Cherezov V., Stevens R.C. Structure of an agonist-bound human A2A adenosine receptor. Science 2011, 332:322-327.